

Reference number(s) 4803-A

# Jurisdiction Specific Medicare Part B Subcutaneous Immune Globulin (SCIG)

## **Products Referenced by this Document**

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
HYQVIA	immune globulin infusion 10% [human] with recombinant human hyaluronidase

#### **Covered Uses**

The indication below is considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- Primary Immunodeficiency (PI)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

## **Coverage Criteria**

#### Primary Immunodeficiency (PI)

Authorization of 1 month may be granted for treatment of adults and pediatric patients 2 years of age or older with primary immunodeficiency (PI), including, but not limited to, any of the following conditions when SCIG will be used for a maximum of 2 episodes (doses) to provide teaching in the office setting:

Common variable immunodeficiency (CVID)

SCIG MedB Jurisdiction 05 and 08 (IA KS MO NE IN MI) 4803-A P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s) 4803-A

- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich syndrome
- Severe combined immunodeficiencies

## Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)<sup>1-3</sup>

Authorization of 1 month may be granted for treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) for a maximum of 2 episodes (doses) to provide teaching in the office setting.

### References

- Intravenous Immune Globulin (SCIG) LCD (L34771) Version R22. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed May 15, 2024.
- 2. Billing and Coding: Immune Globulins (A57554) Version R9. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed May 15, 2024.
- 3. HyQvia [package insert]. Lexington, MA: Baxalta US Inc.; January 2024.